Exelixis PI3K/mTOR Inhibitor XL765 effective in Phase I

Phase I data presented at the EORTC-NCI-AACR Symposium show Exelixis PI3K/mTOR kinase inhbitor XL765  to show  demonstrate ‘robust pharmacodymanics’

Exelixis IGF-1R/Src inhibitor XL228 effective in Phase I

Phase I data presented at the EORTC-NCI-AACR Symposium show Exelixis’ IGF-1R/Src inhibitor  XL228 to show signs of Clinical Benefit inpatients with advanced malignancies

Boehringer Ingelheim PLK1 inhibitor BI6727 effective in Phase I

Phase I data presented at the EORTC-NCI-AACR meeting shows Boehringer Ingelheim’s PLK-1 inhibitor BI-6727 to be safe and to demonstrate potential anti-tumor activity in patients with advanced tumors who have failed to respond to other treatments.

Piramal initate Phase I trial with CDK4 inhibitor P-1446A-05

Piramal are initiating a Phase I trial of CDK4 inhibitor P-1446A-0 in Canada

Inspire initiate Phase I trial of Rho kinase I inhibitor INS117548 in Glaucoma

Inspire have initiated a Phase I trial of Rho kinase I inhibitor INS117548 in patients with Glaucoma

VGX Pharmaceuticals VGX-1027 safe in Phase I

VGX Pharmaceuticals have released results of a Phase I study of NfkappaB/p38 inhibitor VGX-1027 showing it to be safe and well tolerated. A multiple ascending dose (MAD) has now been initiated

Inspire to initiate Phase I for Rho kinase inhibitor INS117548 in Glaucoma

Inspire Pharmaceuticals have announced that it will shortly commence a Phase I clinical trial of INS117548 Ophthalmic Solution for the treatment of glaucoma

Five Prime initiate Phase I trial of FGFR1:Fc fusion protein

Five Prime have initiated a Phase I trial of its FGFR1:Fc fusion protein FP-1039, in patients with advanced solid tumors.

Plexxicon initiate Phase I trial with kinase inhibitor in Pain and Polycystic Kidney Disease

Plexxicon have initiated a Phase I trial with a kinase inhibitor in Pain and Polycystic Kidney Disease. The target has not been disclosed

AVEO initiate Phase Ib trial with VEGFR inhibitor AV-951

AVEO Pharmaceuticals has initiated a Phase Ib clinical study its  VEGFR 1/2/3 receptor inhibitor AV-951.